2024 Allogeneic Hematopoietic Stem Cell Transplantation in Immunodeficiency-Centromeric Instability-Facial Dysmorphism (ICF) Syndrome: an EBMT/ESID Inborn Errors Working Party Study Group Inborn Errors Working Party (IEWP) Other society 1st listed author Dagmar Berghuis Journal J Clin Immunol.
2024 Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Razan Mohty Journal Bone Marrow Transplant.
2024 Young (<35 years) haploidentical versus old (≥35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Bone Marrow Transplant.
2024 Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS Group Cellular Therapy & Immunobiology Working Party (CTIWP) 1st listed author Esteban Arrieta-Bolaños Journal Blood.
2024 The EBMT-ADWP and the CIBMTR Group Autoimmune Diseases Working Party (ADWP) Other society 1st listed author Raffaella Greco Journal Handb Clin Neurol.
2024 ATG and other serotherapy in conditioning regimens for autologous HSCT in autoimmune diseases: a survey on behalf of the EBMT Autoimmune Diseases Working Party (ADWP) Group Autoimmune Diseases Working Party (ADWP) 1st listed author Azza Ismail Journal Bone Marrow Transplant.
2024 Half a century of healing: celebrating the 50th anniversary of EBMT 1st listed author Eliane Gluckman Journal Bone Marrow Transplantation
2024 How risky is a second allogeneic stem cell transplantation? Group Transplant Complications Working Party (TCWP) 1st listed author Olaf Penack Journal Leukemia.
2024 Impact of the type of tyrosine kinase inhibitor (imatinib or dasatinib) used before allo-HCT on outcome of patients with Philadelphia-positive acute lymphoblastic leukemia. A study on behalf of the Acute Leukemia Working Party of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Sebastian Giebel Journal Transplant Cell Ther.
2024 PTCy vs CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT Group Lymphoma Working Party (LWP) 1st listed author Juan Montoro Journal Blood Adv.
2024 Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group Group Infectious Diseases Working Party (IDWP) 1st listed author Anne Mea Spanjaart Journal Leukemia.
2024 Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: Collection of real-world data in the context of hematopoietic cellular therapies Group WP/Committee not specified 1st listed author Christian Chabannon Journal Best Practice & Research Clinical Haematology